aacp hero banner

Latest News

Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of NCOA.

NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026

NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026

November 18, 2026

OncLive Staff


Galinpepimut-S Improves OS in AML in Second or Later Remission

Galinpepimut-S Improves OS in AML in Second or Later Remission

November 18, 2026

Ryan Kret


Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

November 18, 2026

OncLive Staff


Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC

Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC

November 18, 2026

OncLive Staff


FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma

FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma

November 17, 2026

Chris Ryan


Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training

November 17, 2026

OncLive Staff


Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer

Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer

November 17, 2026

OncLive Staff


Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC

Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC

November 17, 2026

OncLive Staff


FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis

FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis

November 17, 2026

Ryan Kret


FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC

FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC

November 17, 2026

Riley Kandel


CD83 CAR T Cells Can Take the Reins When CD19 CAR T Cells Lose Their Punch

CD83 CAR T Cells Can Take the Reins When CD19 CAR T Cells Lose Their Punch

November 17, 2026

Roswell Park Comprehensive Cancer Center


TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma

TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma

November 17, 2026

Sidharth Rastogi


Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer

Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer

November 16, 2026

OncLive Staff


Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer

Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer

November 16, 2026

Ryan Kret


Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC

Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC

November 16, 2026

Ryan Kret